ETIHX news

Eventide Healthcare & Life Sciences Fund · United States

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

wallstreet:online · 27 Oct 2026, 20:05 UTC
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
3.5% of ETIHX
The Manila times · 27 Oct 2026, 20:21 UTC
Revolution Medicines to Participate in November 2026 Investor Conferences
2.4% of ETIHX
The Manila times · 27 Oct 2026, 11:45 UTC
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
2.8% of ETIHX
Market Screener · 28 Oct 2026, 13:52 UTC
DexCom, Inc. Launches Dexcom G7 15 Day Continuous Glucose Monitoring System In Canada
1.0% of ETIHX
Where to buy ETIHX
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
wallstreet:online · 26 Oct 2026, 12:00 UTC
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
3.5% of ETIHX
Market Screener · 28 Oct 2026, 12:21 UTC
United Therapeutics Corporation Receives FDA Clearance To Proceed With Clinical Trial For Treprostinil-Iloprost SMI In Pulmonary Arterial Hypertension
0.8% of ETIHX
Where to buy ETIHX
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
RTTNews · 28 Oct 2026, 11:38 UTC
United Therapeutics Gets FDA Clearance To Begin Trial Of Inhaled PAH Therapy
0.8% of ETIHX
Investing.com · 28 Oct 2026, 11:12 UTC
United Therapeutics gets FDA nod for PAH combination therapy trial By Investing.com
0.8% of ETIHX
wallstreet:online · 28 Oct 2026, 11:05 UTC
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
0.8% of ETIHX
Financial Post · 28 Oct 2026, 00:00 UTC
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
1.0% of ETIHX
Seeking Alpha · 27 Oct 2026, 07:31 UTC
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy (NASDAQ:CGON) | Seeking Alpha
1.5% of ETIHX
Financial Post · 26 Oct 2026, 00:00 UTC
Definium Therapeutics Announces New Employee Inducement Grants
1.9% of ETIHX
Investing.com · 27 Oct 2026, 09:44 UTC
Why is Dianthus Therapeutics stock gaining today? By Investing.com
1.2% of ETIHX
Markets Insider · 26 Oct 2026, 03:20 UTC
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Boston Scientific (BSX)
2.6% of ETIHX
Markets Insider · 27 Oct 2026, 01:37 UTC
BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
1.3% of ETIHX
The Manila times · 27 Oct 2026, 20:21 UTC
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
0.7% of ETIHX
Market Screener · 26 Oct 2026, 20:20 UTC
Oruka Therapeutics, Inc. Announces Positive Week 16 Results for Orka-001 from the Ongoing Everlast-B Trial in Moderate-To-Severe Psoriasis
1.3% of ETIHX
Seeking Alpha · 27 Oct 2026, 17:01 UTC
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer - Slideshow (NASDAQ:TNGX) 2026-10-27 | Seeking Alpha
0.7% of ETIHX
Seeking Alpha · 25 Oct 2026, 18:56 UTC
Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside (NASDAQ:IONS) | Seeking Alpha
2.5% of ETIHX
Seeking Alpha · 26 Oct 2026, 16:50 UTC
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow (NASDAQ:ORKA) 2026-10-26 | Seeking Alpha
1.3% of ETIHX